A229000 Stock Overview
Provides diagnostic solutions in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Gencurix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,804.00 |
| 52 Week High | ₩4,900.00 |
| 52 Week Low | ₩1,131.00 |
| Beta | 0.14 |
| 1 Month Change | 0.61% |
| 3 Month Change | -22.07% |
| 1 Year Change | -61.16% |
| 3 Year Change | -88.01% |
| 5 Year Change | -88.65% |
| Change since IPO | -88.62% |
Recent News & Updates
Shareholder Returns
| A229000 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -3.9% | 0.7% | -0.7% |
| 1Y | -61.2% | 3.3% | -5.5% |
Return vs Industry: A229000 underperformed the KR Medical Equipment industry which returned 3.3% over the past year.
Return vs Market: A229000 underperformed the KR Market which returned -5.5% over the past year.
Price Volatility
| A229000 volatility | |
|---|---|
| A229000 Average Weekly Movement | 19.2% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in KR Market | 12.9% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A229000's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A229000's weekly volatility has increased from 12% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 72 | Sung-Rai Cho | www.gencurix.com |
Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detection. The company was founded in 2011 and is headquartered in Seoul, South Korea.
Gencurix Inc. Fundamentals Summary
| A229000 fundamental statistics | |
|---|---|
| Market cap | ₩29.61b |
| Earnings (TTM) | -₩12.55b |
| Revenue (TTM) | ₩3.39b |
8.4x
P/S Ratio-2.3x
P/E RatioIs A229000 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A229000 income statement (TTM) | |
|---|---|
| Revenue | ₩3.39b |
| Cost of Revenue | ₩1.28b |
| Gross Profit | ₩2.11b |
| Other Expenses | ₩14.66b |
| Earnings | -₩12.55b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -794.09 |
| Gross Margin | 62.26% |
| Net Profit Margin | -369.77% |
| Debt/Equity Ratio | 105.4% |
How did A229000 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/03 14:05 |
| End of Day Share Price | 2025/02/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gencurix Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|